Summary
This structural and mechanistic study identifies a novel class of antibiotics that target the lipopolysaccharide (LPS) transport machinery of Gram-negative bacteria, specifically Acinetobacter. The antibiotics function by trapping a substrate-bound conformational state of the LPS transporter, thereby stalling its function through recognition of a composite binding site formed by both the transporter protein and its LPS substrate. The findings reveal a previously unexploited druggable state of the LPS transporter and provide a foundation for extending this antibiotic class to other clinically significant Gram-negative pathogens.
UK applicability
As a fundamental discovery concerning a novel antibiotic mechanism, these findings are globally relevant to the treatment of Gram-negative bacterial infections, including those of clinical importance in the United Kingdom. The work may inform future antibiotic development strategies for resistant pathogens, though direct application to UK clinical practice would require further translational work and regulatory approval.
Key measures
Structural characterisation of antibiotic–LPS transporter complexes; biochemical inhibition assays; genetic validation of mechanism
Outcomes reported
The study characterised a new class of antibiotics that inhibit the lipopolysaccharide (LPS) transport machinery in Acinetobacter by trapping a substrate-bound conformation of the LPS transporter. Structural, biochemical and genetic analyses revealed the mechanism by which these inhibitors recognise a composite binding site formed by both the transporter and its LPS substrate.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.